A phase 1 photoswitch trial in advanced retinitis pigmentosa
2026-04-14 · Reviewed 2026-10-07
Nature Medicine reported a first-in-human safety study of KIO-301 in six people with advanced retinitis pigmentosa. It is not a longevity study.
Casson and colleagues published the trial in Nature Medicine on 14 April 2026. This page paraphrases the abstract. It does not copy the paper, and it does not turn a retinal disease study into an anti-aging method.
Biological mechanism
The abstract describes KIO-301 as a small azobenzene photoswitch meant to make retinal ganglion cells respond to light. That is not the same as claiming a gene therapy for aging.
What was reported
The primary safety outcome was met in this small study: no serious adverse events and no dose-limiting toxicities are reported in the abstract.
Organism
Human. Six participants, 12 eyes, advanced retinitis pigmentosa.
Main results
Safety over 30 days was the primary outcome. Exploratory light-perception and functional-vision measures varied. The abstract names ClinicalTrials.gov NCT05282953.
Limitations
Open-label, nonrandomized, six participants, primary follow-up of 30 days in the abstract. Exploratory vision findings are not a proof of restored sight for everyone with the disease.
Known risks
The abstract says ocular adverse events were mild and related to the injection procedure. This page is not a guide to obtaining an intravitreal drug.
What is still unproven
Larger trials would be needed for efficacy. Nothing here shows an effect on human lifespan.
Scientific sources
- Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial Casson RJ, Daniels E, Barras CD, Dwyer A, Strem BM, Wykoff CC, Gregorio-King C, Schuh C, Kramer RH, Van Gelder RN. Nature Medicine, 2026-04-14. DOI 10.1038/s41591-026-04317-6
Related notes
Educational information, not medical advice. This site does not publish experimental protocols for personal use and does not recommend genetic therapies, senolytics, or experimental drugs.